I can already tell you that no matter how air tight the data is, there will be someone who attempts to invalidate it or downplay it. Only third party validation, either a respected journal or the FDA itself, will prevent a drop in the share price.
If Blarcamesine works, patients will demand it and doctors will be forced to either Rx it or risk seeing patients find a more willing provider. Shareholders will be rewarded either through increasing revenue from which future cash flows can be modeled, or through a buyout if someone decides they want all those profits.
No blogger or message board poster can stop the ball from rolling downhill at this point. This is why Dr. Missling isn’t responding. His focus isn’t on the short term stuff that is irrelevant to the long term.
Patient shareholders will either be punished severely or rewarded well.